Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer have?

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer has 261 citations in the OpenAlex counts ScholarIQ stores.

When was Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer published?

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer has 2019 year in the ScholarIQ index.

What is the open-access status of Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?

Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer has closed oa status in the ScholarIQ index.

What is the DOI of Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?

The DOI for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is on the source record.

What is the PMID of Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?

The PMID for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is on the source record.

What is the OpenAlex record for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer?

The OpenAlex for Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer is on the source record.